Invesco Ltd.
At today's price, Invesco Ltd. (IVZ) is priced for today's economics sustained for ~5.8 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• Invesco is a global asset manager that earns fees on assets under management, which the 10-K describes as services ⟦"satisfied over time"⟧ tied to the value of the AUM, so revenue rises and falls with markets and with net flows. • The counterintuitive point is that the trailing operating line is negative, dragged down by a non-cash charge, even as the business is running record assets and an adjusted operating margin of 34.5%, so the reported GAAP picture understates the underlying earnings po
Is IVZ overvalued? See what's priced in →
611 institutional managers reported holding IVZ in 13F filings for the quarter ended 2026-03-31. Together they hold about 92% of the company; the top 10 hold 62%. 78 opened new positions that quarter. Held by Vanguard Group, BlackRock, Millennium Management, among others. On the short side, 17.0M shares were sold short as of the 2026-06-15 count, about 4% of shares outstanding (3.2 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
IVZ has cut its share count 2.5% over the past five years, spending $717.90M on repurchases. It pays a dividend, and has paid one every year in our records (18 and counting), raised 4 years straight; the current rate is $0.83 a share annually. Cash returned over the past three years: $1.02B in dividends and $280.70M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at IVZ over the trailing three years. Absence is a fact about the company, not a signal. 20 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
IVZ's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-03 | -8.5% | -18.0% |
| 2023-11-01 | +0.6% | +32.1% |
| 2024-02-22 | -5.6% | -7.1% |
| 2024-05-02 | -6.8% | +3.6% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
IVZ's latest 8-K filings: 2026-07-10 (items 7.01, 9.01); 2026-06-09 (items 7.01, 9.01); 2026-05-22 (items 5.07); 2026-05-11 (items 7.01, 9.01); 2026-04-28 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.